WuXi Biologics Signs $1.5 Billion Pact with GSK for Four Novel TCE Antibodies

WuXi Biologics out-licensed global rights for up to four pre-clinical bi- & multi-specific TCE antibodies to GSK in a $1.5 billion agreement. TCEs are antibody-based immunotherapies that redirect T cells to kill cancer cells. Initially, GSK will have rights to a pre-clinical bispecific antibody that crosslinks tumor cells and T cells by targeting a tumor-associated antigen (TAA) on tumor cells and CD3 expression on T cells. GSK may exercise rights for up to three additional earlier-stage pre-clinical TCE antibodies. WuXi Biologics will receive $40 million upfront and up to $1.46 billion in milestones for the four TCE antibodies, plus royalties. More details....

Stock Symbols: (HK: 2269) (NYSE: GSK)

Share this with colleagues: